ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

February 22, 2008 15:06 ET

ALDA Receives Australian Patent for T36®

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 22, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") is pleased to announce that Australian Patent Number 2002322916 has been issued by the Australia Patent Office. The patent provides protection for the composition and production methods for ALDA's T36® formulation until August 20, 2022.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    or
    ALDA Pharmaceuticals Corp.
    Peter Chen
    Distribution & Sales Contact
    (604) 521- 8300 Ext. 3
    (604) 521-8322 (FAX)
    Email: peter_chen@aldacorp.com
    or
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    (604) 288-7222
    Email: syoung@freeformcom.com
    Website: www.aldacorp.com